Mirati Therapeutics Inc (MRTX) Major Shareholder Venbio Select Advisor Llc Sells 23,781 Shares
Mirati Therapeutics Inc (NASDAQ:MRTX) major shareholder Venbio Select Advisor Llc sold 23,781 shares of the company’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $72.80, for a total value of $1,731,256.80. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Venbio Select Advisor Llc also recently made the following trade(s):
- On Monday, March 18th, Venbio Select Advisor Llc sold 125,000 shares of Mirati Therapeutics stock. The stock was sold at an average price of $76.55, for a total value of $9,568,750.00.
- On Wednesday, February 20th, Venbio Select Advisor Llc sold 686,820 shares of Mirati Therapeutics stock. The stock was sold at an average price of $73.00, for a total value of $50,137,860.00.
Shares of NASDAQ:MRTX traded down $0.42 during trading on Wednesday, hitting $72.77. The company had a trading volume of 446,032 shares, compared to its average volume of 734,769. The firm has a market capitalization of $2.69 billion, a price-to-earnings ratio of -22.81 and a beta of 2.12. Mirati Therapeutics Inc has a one year low of $24.65 and a one year high of $80.00.
MRTX has been the subject of several research analyst reports. Oppenheimer set a $81.00 target price on Mirati Therapeutics and gave the stock a “buy” rating in a research report on Thursday, March 7th. Piper Jaffray Companies initiated coverage on Mirati Therapeutics in a research report on Friday, February 15th. They set an “overweight” rating and a $85.00 target price for the company. Zacks Investment Research cut Mirati Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, March 7th. Svb Leerink reiterated an “outperform” rating on shares of Mirati Therapeutics in a research report on Friday, February 15th. Finally, Cantor Fitzgerald initiated coverage on Mirati Therapeutics in a research report on Monday, March 4th. They set a “neutral” rating and a $66.00 target price for the company. Four investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $67.20.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.watchlistnews.com/mirati-therapeutics-inc-mrtx-major-shareholder-venbio-select-advisor-llc-sells-23781-shares/2905035.html.
About Mirati Therapeutics
Mirati Therapeutics, Inc, a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC.
Further Reading: What is the strike price in options trading?
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.